英集芯回应监管关注，称脑机接口芯片暂未实现规模化销售

Core Viewpoint - The brain-computer interface (BCI) concept is gaining traction, with several listed companies, including Yingjixin, entering the market with new products aimed at this technology [1][2]. Group 1: Company Developments - Yingjixin announced the launch of the IPA1299 chip, a low-noise, 8-channel, 24-bit synchronous sampling analog-to-digital converter (ADC) designed for applications in electroencephalography (EEG), electrocardiography (ECG), and electromyography (EMG) [1]. - The IPA1299 chip is noted for its high-precision signal acquisition capabilities, making it suitable for non-invasive brain-computer interface applications [1]. - The company holds a 15% stake in its partner, Jingxin Weier, which was established in September 2023 with a registered capital of 1.1765 million yuan [1]. Group 2: Market Position and Financials - Yingjixin's revenue for the first three quarters of 2025 was reported at 1.169 billion yuan, with a net profit attributable to shareholders of 114 million yuan [2]. - The company indicated that the IPA1299 chip has already entered mass production and its performance parameters are competitive with leading overseas chip products [2]. - Despite the promising technology, the non-invasive BCI market is still in its cultivation phase, and significant sales have not yet been realized, leading to uncertainty in future sales [1].